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Background: The mechanism by which Tks4 
regulates action cytoskeleton is largely 
unknown.  
Results: In response to EGF treatment, Tks4 is 
tyrosine phosphorylated and associated with 
the EGF receptor.  
Conclusion: The results provide a new 
mechanism of regulating cell migration.  
Significance: Tks4 can be targeted in 
regulation of tumor cell migration.  
 
 
SUMMARY 
Mutations in the SH3PXD2B gene coding 
for the Tks4 protein are responsible for the 
autosomal-recessive Frank-ter Haar 
syndrome. Tks4, a substrate of Src tyrosine 
kinase is implicated in the regulation of 
podosome formation. Here, we report a 
novel role for Tks4 in the EGF signalling 
pathway. In EGF-treated cells, Tks4 is 
tyrosine phosphorylated and associated with 
the activated EGF receptor. This association 
is not direct but requires the presence of Src 
tyrosine kinase. In addition, treatment of 
cells with LY294002, an inhibitor of PI 3-
kinase, or mutations of the PX domain 
reduces tyrosine phosphorylation and 
membrane translocation of Tks4. 
Furthermore, a PX domain mutant (R43W) 
Tks4 carrying a reported point mutation in 
a Frank-ter Haar syndrome patient showed 
aberrant intracellular expression and 
reduced phosphoinositide binding. Finally, 
silencing of Tks4 was shown to markedly 
inhibit HeLa cell migration in a Boyden 
chamber assay in response to EGF or 
serum. Our results therefore reveal a new 
function for Tks4 in the regulation of 
growth factor-dependent cell migration. 
______________________________________ 
 
    Epidermal growth factor receptor (EGFR) is 
involved in diverse cellular processes, 
including proliferation and motility; however, 
it is also implicated in the development of 
various human cancers (1). Binding of EGF to 
its receptor at the plasma membrane induces 
dimerization of EGFR, which results in the 
autophosphorylation and activation of EGFR 
(2) A number of signaling pathways have been 
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identified through which EGFR may regulate 
rearrangement of the actin cytoskeleton, such 
as activation of phospholipase Cγ1 (3) and Rho 
GTPases (4,5). Tyrosine kinases of the Src 
family are also involved in transmitting signals 
downstream of EGFR and other receptors, and 
a variety of Src substrates are known to 
regulate actin cytoskeleton (6).  
     Tks5/FISH was first identified as a Src 
substrate possessing one phox homology (PX) 
domain on its N-terminus and five Src 
homology (SH3) domains (7). Tks5 was shown 
to be localized at the podosomes of Src-
transformed cells and associated with some 
members of the ADAM metalloprotease family 
(8). Later, Tks5 was found to be expressed in 
podosomes in invasive cancer cells. In 
addition, Tks5 expression was required for 
protease-driven matrigel invasion in human 
cancer cells (9). In this process Nck adaptor 
proteins, Nck1 and Nck2, seem to link Tks5 to 
invadopodia actin regulation and extracellular 
matrix degradation (10). Finally, Tks5 has 
been shown to be required for migration of 
neural crest cell during development of 
zebrafish embryos (11). 
     Recently, a homolog of Tks5, Tks4, has 
been identified and shown to also influence 
podosomes in cells (12). Tks4 has similar 
domain architecture as that of Tks5, containing 
one PX domain and four SH3 domains (12). 
Tks4 was also implicated in the production of 
reactive oxygen species (ROS) by tumor cells 
(13-15), and in the differentiation of white 
adipose tissue (16). Intriguingly, in two 
independent mouse models, the absence of 
Tks4 resulted in abnormal development 
causing runted growth, craniofacial and 
skeletal abnormalities, hearing impairment, 
glaucoma and the virtual absence of white 
adipose tissue (17,18). In humans, the Tks4-
deficiency is responsible for the development 
of Frank-ter Haar syndrome (18). Recently, we 
have shown that Tks4 is instrumental for the 
development of EGF-induced membrane 
ruffles and lamellipodia as well as for efficient 
cellular attachment and spreading of HeLa 
cells (19). In addition, it has been 
demonstrated that Tks4 associates with Src 
tyrosine kinase and cortactin, a well-
established activator of Arp2/3 complex (19).   
     In this study we have investigated the 
mechanism by which Tks4 contributes to EGF 
signaling. We demonstrate that Tks4 is 
tyrosine phosphorylated and associated with 
the activated EGF receptor upon EGF 
stimulation of cells. This association is not 
direct but requires the presence of Src tyrosine 
kinase. In addition, the PX domain is 
instrumental for the proper translocation of 
Tks4 to membrane ruffles in EGF-treated cells. 
A PX domain mutant (R43W) Tks4 carrying a 
reported point mutation in a Frank-ter Haar 
syndrome patient showed aberrant intracellular 
expression and reduced phosphoinositide 
binding. Finally, silencing of Tks4 was shown 
to markedly inhibit HeLa cell migration in 
response to EGF or serum. Our results 
therefore reveal a new function for Tks4 in the 
regulation of growth factor-dependent cell 
migration. 
 
EXPERIMENTAL PROCEDURES 
Antibodies, constructs and reagents. 
Antibodies against the EGF receptor (06-847) 
and phosphotyrosine residues (clone 4G10, 05-
321) were obtained from Millipore (Billerica, 
MA). Antibodies against the V5 epitope 
(R96025 and A7345) were purchased from 
Invitrogen (Carlsbad, CA) and Sigma-Aldrich 
(St. Louis, MO), respectively. Antibodies 
against GST (sc-459) and Src (2109) were 
from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA) and Cell Signaling Technologies 
(Beverly, MA), respectively. Antibody against 
β-actin (A5316) was obtained from Sigma-
Aldrich (St. Louis, MO). Alexa Flour 488 goat 
anti-rabbit (A11008) and Alexa Flour 488 
rabbit anti-mouse (A11059) antibodies were 
purchased from Invitrogen (Carlsbad, CA). 
Generation of polyclonal anti-Tks4 antibody 
was described earlier (19). The V5 epitope-
tagged Tks4 and PX domain of Tks4 expressed 
as GST fusion protein were described 
previously (19). V5-Tks4Y25,373,508F, V5-
Tks4R71,94L, V5-Tks4R43Q, V5-Tks4R43W, as well 
as GST-PXR43W mutants were generated using 
the QuickChange Site-directed Mutagenesis 
Kit (Stratagene, La Jolla, CA). cDNA of full 
length Src in mammalian expression vector 
pCMV6 was purchased from OriGene 
Technologies, Inc.  Chicken ∆SH2 Src and 
∆SH3 Src constructs subcloned into the 
mammalian expression vector pSGT were 
obtained from the laboratory of Giulio Superti-
Furga (Vienna, Austria). Stock solutions of 
epidermal growth factor (EGF, Sigma-
Aldrich), PP1 (Biomol, Hamburg, Germany), 
and LY294002 (Merck, Darmstadt, Germany) 
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were prepared according to the manufacturer’s 
instructions.  
     Cell lines, transfection, and stimulation. 
A431, COS7, and HeLa cells were purchased 
from American Type Culture Collection and 
maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% 
fetal calf serum (Invitrogen), penicillin (100 
units/ml), and streptomycin (50 µg/ml). All 
cell lines were transiently transfected with 
Lipofectamine (Invitrogen) according to the 
manufacturer’s instructions. For stimulation, 
cells were serum-starved overnight and 
stimulated with EGF at 50 ng/ml for 10 min. 
Alternatively, cells were pre-treated with the 
PI 3-kinase inhibitor LY294002 at 20 µM or 
the Src inhibitor PP1 at 20 µM for 60 min and 
then stimulated with EGF as above.  
     Chemoinvasion assay. Boyden chamber 
invasion assays were carried out on HeLa cells 
48 h after Stealth siRNA transfection. The 
Millipore QCM Cell Migration Assay 
(ECM508) was used according to the 
manufacturer’s instructions with the 
modification that the membrane surface of 
each chamber was coated with 10 µg of 
collagen type I (Sigma-Aldrich, C8919) for 1 h 
in a 37 °C incubator, washed briefly in PBS 
and air dried. 1,5 x 105 cells in DMEM 
medium were added to the upper chamber and 
allowed to penetrate the porous membrane (8 
µm) to the bottom chamber containing EGF 
(100 ng/ml) or 10% FBS. Cells on the top 
surface of the membrane were removed after 
24 h incubation, and the cells on the bottom 
surface were quantified.  
     Confocal microscopy. COS7 cells plated on 
glass cover slips were transiently transfected 
with different Tks4 constructs as indicated and 
then serum starved overnight. Cells were 
pretreated with 20µM LY294002 for 60 
minutes and then treated with 50 ng/mL EGF 
for 10 minutes. After treatment cells were 
fixed in 4% paraformaldehyde-PBS for 15 
minutes, permeabilized in 0.2% Triton X-100 
in PBS for 5 minutes, and blocked with 1% 
BSA in PBS for 20 minutes. Anti-Tks4 rabbit 
serum was applied in 1:1000 dilution for 30 
minutes. After washing with PBS the samples 
were incubated with Alexa Fluor 488 labelled 
anti-mouse secondary antibody or anti-rabbit 
antibody (for staining endogenous Tks4) for 30 
minutes. After 40 minutes of washing with 
PBS cover slips were mounted onto slides in a 
100 mM Tris–HCl puffer, pH 8.5, containing 
10% Mowiol 4-88 (Calbiochem), 25% 
glycerol, and 2.5% 1,4-diazobicyclo-
[2.2.2]octane (DABCO, Sigma-Aldrich). Tks4 
membrane-localization was quantified by 
counting at least 100 cells/sample. Microscopy 
was performed on a Nikon Eclipse E400 
fluorescence microscope or Zeiss LSM 710 
confocal microscope. 
     Lipid binding assay. PIP strips membranes 
were obtained from Invitrogen (#P23750). 
Protein-lipid overlay experiments were 
performed using GST-PX (aa 1-130) and GST-
PXR43W  fusion proteins following the 
manufacturer’s protocol.  
     siRNA transfection and siRNA-resistant 
mutant of Tks4. Silencing of Tks4 was 
achieved by transfecting HeLa cells (50% 
confluent) with specific stealth siRNA duplex 
(GCCUGAUACCAAUUGAUGAAUACUG) 
or non-targeting 
(GCCGGAUACCAAUUGAUUAACAUUG) 
stealth siRNA duplex in a final concentration 
of 40 nM using Lipofectamine RNAiMAX 
Reagent (Invitrogen). Two days after 
transfection, the cells were used for 
experiments and the knockdown was verified 
by western blotting of equal protein amounts 
of lysates from control and Tks4-silenced cells. 
To rescue the phenotype of Tks4 siRNA, an 
siRNA-resistant mutant of V5-Tks4 was 
created by substituting five nucleotides in the 
Tks4 siRNA targeting region 
(GCCTGATCCCCATCGATGAGTATTG).  
     Statistics. All quantitative results are 
presented as the mean and s.d. of (at least 3) 
independent experiments. Statistical 
differences between two groups of data were 
analyzed by Student’s t-test.  
 
RESULTS 
     EGF induces tyrosine phosphorylation of 
Tks4 and its interaction with the EGFR. We 
have investigated if Tks4 is involved directly 
in the EGF signaling pathway.  Serum-starved 
A431 cells were stimulated with EGF for 10 
min or left untreated and then endogenous 
Tks4 was immunoprecipitated with a 
polyclonal anti-Tks4 antibody. As seen in Fig 
1a, Tks4 is subject of tyrosine phosphorylation 
in response to EGF stimulation. In addition, 
the activated EGFR was coimmunoprecipitated 
with the scaffold protein. Interestingly, a 150 
kDa phosphotyrosine protein was also 
consistently observed in the 
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immunoprecipitates, although the association 
of this unknown protein seemed to be 
independent of growth factor treatment. To 
confirm the involvement of Tks4 in the EGF 
signaling pathway in another cell system, V5 
epitope-tagged Tks4 was transiently 
overexpressed in COS7 cells, then after EGF 
stimulation Tks4 was immunoprecipitated with 
an anti-V5 antibody. Fig 1b demonstrates that 
in this system Tks4 is also tyrosine 
phosphorylated upon EGF treatment and 
associates with the autophosphorylated EGFR. 
These results establish a novel interaction 
between Tks4 and the EGFR, implicating Tks4 
in growth factor signaling pathways.  
     Src is required for EGF-dependent Tks4 
phosphorylation. Considering the structure of 
Tks4, it seemed unlikely that it could associate 
directly with the tyrosine kinase receptor. 
Since both Tks4 and its close kin Tks5 are 
prominent substrates of the Src tyrosine kinase 
implicated in podosome formation (7-9,12), we 
proposed that Src might function as a linker 
between Tks4 and the EGFR as described for 
many other protein complexes (20). To 
challenge our hypothesis, first, COS7 cells 
were transiently transfected with V5-Tks4 
construct and then pre-treated with PP1, a 
specific inhibitor of Src. Following EGF 
treatment V5-Tks4 was immunoprecipitated 
and subjected to anti-phosphotyrosine 
immunoblot. The inhibitor markedly decreased 
tyrosine phosphorylation of Tks4 (Fig 2a). A 
previous study has shown that Src kinase 
phosphorylates Tks4 on three tyrosine residues 
(12). Therefore, we introduced point mutations 
into Tks4, changing tyrosines 25, 373, and 508 
to phenylalanines, respectively. V5-
Tks4Y25,373,508F was transiently expressed in 
COS7 cells, then after serum starvation cells 
were treated with EGF. Tks4 was 
immunoprecipitated from lysates with anti-V5 
antibody. The anti-phosphotyrosine 
immunoblot demonstrated that 
phosphorylation of the triple mutant protein is 
significantly decreased upon EGF treatment 
(Fig 2b). It is worth noting that the expression 
level of the triple Tks4 mutant is somewhat 
reduced compared to that of the wild type, 
nevertheless it is clearly not able to be 
phosphorylated, as indicated by the 
densitometry of the appropriate bands (Fig. 
2b). Next, we examined if Src tyrosine kinase 
could associate with Tks4. To this end, COS7 
cells were transiently transfected with V5-Tks4 
construct and then stimulated with EGF or left 
untreated. Tks4 proteins were 
immunoprecipitated with anti-V5 antibody and 
subjected to anti-Src immunoblot. Fig 2c 
demonstrates that EGF treatment of the cells 
induced the association of Tks4 with Src. To 
prove that Src functions as an adaptor 
molecule linking EGFR to Tks4, wild type Src 
and Src mutants lacking either the SH2 (∆SH2 
Src) or the SH3 (∆SH3 Src) domains were co-
expressed with V5-Tks4 in COS7 cells. As Fig 
2d demonstrates, expression of either ∆SH2 
Src or ∆SH3 Src inhibited the association of 
Tks4 with EGFR, while expression of wild 
type Src did not interfere with the interaction. 
We have to note that when overexpressed all 
Src constructs seem to be co-
immunoprecipitated with Tks4 independent of 
cell stimulation. These results collectively 
suggest that Src kinase serves as a linker 
between the receptor and the scaffold protein 
and is responsible for Tks4 phosphorylation in 
response to EGF stimulation.  
     PX domain is instrumental for Tks4 
function. The family of Tks proteins possesses 
a Phox homology (PX) domain which can bind 
specific membrane lipids and is implicated in 
the appropriate cellular localization of Tks4 
and Tks5 (7-9,12). Therefore, we asked if the 
PX domain is required for tyrosine 
phosphorylation and proper subcellular 
localization of Tks4. First, V5 epitope-tagged 
wild type Tks4 was transiently expressed in 
COS7 cells, and then cells expressing V5-Tks4 
were stimulated with EGF or left untreated. As 
shown in Fig 3a, EGF-dependent 
phosphorylation of the scaffold protein could 
be inhibited by addition of the specific PI 3-
kinase inhibitor LY294002. To confirm that 
the intact PX domain is instrumental for the 
adequate tyrosine phosphorylation, point 
mutations were introduced into the PX domain 
of Tks4 changing the conserved arginines 71 
and 94 to leucines, as described earlier for 
other PX domains (21-23). Fig 3b 
demonstrates that the mutations introduced 
reduced the tyrosine phosphorylation of Tks4 
despite the fact that the expression level of the 
mutant Tks4 in COS7 cells was somewhat 
lower. To further examine the roles of PX 
domain in the function of Tks4, subcellular 
rearrangement of endogenous Tks4 was 
studied using immunofluorescence 
microscopy. In quiescent COS7 cells, Tks4 
showed a uniform cytoplasmic distribution, 
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with membrane localization in only a low 
proportion of cells (approx. 20%). In response 
to EGF, Tks4 was seen to be translocated to 
membrane ruffles in approximately 60% of 
cells (Fig 3c and d). However, when cells were 
pre-treated with LY294002, membrane 
translocation of Tks4 was strongly inhibited. 
These findings suggest that the functional PX 
domain as well as the activation of PI 3-kinase 
is important for the proper EGF-dependent 
tyrosine phosphorylation and membrane 
localization of Tks4.  
     The PX domain mutant of Tks4 is unstable 
intracellularly. Very recently, Iqbal and 
colleagues have identified a family with Frank-
ter Haar syndrome whose Tks4 gene 
(SH3PXD2B) contains a substitution mutation 
which results in the change of the conserved 
arginine 43 to tryptophane in the PX domain 
(18). This mutation was predicted to abolish 
binding to phospholipids (18). We were 
interested to discover if the above mutation 
really impaired the expression and/or the 
function of the protein. The R43W mutant of 
V5 epitope-tagged Tks4 was therefore 
generated and expressed in COS7 cells. As 
shown in Fig 4a, the expression level of the 
mutant protein was significantly decreased 
compared to the wild type form. Intriguingly, 
upon EGF treatment, despite the low 
expression the mutant protein was capable of 
associating with the EGF receptor. It has been 
well established that the PX domain is required 
for lipid binding (24-26). To test directly 
whether the R43W mutation functionally 
inactivates the PX domain, both wild type and 
R43W PX domains were expressed as GST 
fusion proteins and examined in a protein-lipid 
overlay assay, as described earlier (19). Fig 4b 
demonstrates that while the wild type PX 
domain could bind to a selection of different 
phosphoinositides, the R43W mutant was 
practically unable to recognize any of those 
lipids. We have to note that a weak interaction 
of the wild type PX domain was detected with 
phosphatidylserine, which was not seen in our 
previous work (19). Finally, we analyzed the 
intracellular localization of mutant Tks4 
proteins. In a previous study we showed that 
Tks4R43Q mutant is able to be recruited to 
membrane ruffles induced by EGF (19). 
However, quantification of subcellular 
localization of this mutant protein was not 
performed. To compare the subcellular 
localization of the mutant Tks4 proteins in the 
same cell type, both Tks4R43Q and Tks4R43W 
were transiently expressed in COS7 cells 
stimulated with EGF or left untreated. As 
shown in Fig. 4c and 4d, membrane 
localization of both mutants was detected in 
approximately 20% of the cells. However, in 
contrast to wild type Tks4, the mutant proteins 
were not capable of translocating to membrane 
ruffles induced by EGF. Intriguingly, when 
mutant Tks4 proteins were expressed in cells 
both proteins formed aggregates and 
accumulated around the nucleus. It has been 
documented that misfolded and aggregated 
proteins could be sequestered into specialized 
structures named aggresomes (27,28). 
Therefore, it is very likely that both Tks4 
mutants are unstable intracellularly and 
sequestered into aggresomes.  Taken together, 
our data suggests that the R43W mutation 
found in Frank-ter Haar syndrome seriously 
impairs the folding and the function of Tks4 
leading to accelerated degradation of the 
protein.   
     Tks4 is required for EGF-dependent cell 
migration in HeLa cells. We have reported 
recently that Tks4 could associate with 
cortactin, an important protein implicated in 
cell migration (29,30), and regulate cell 
spreading (19). This raised the intriguing 
possibility that Tks4 might contribute to EGF-
dependent cell migration. To analyze the role 
of Tks4 in cell migration, Tks4 was knocked 
down in HeLa cells by means of RNA 
interference, which resulted in a considerable 
degree of reduction of the protein level (Fig. 
5a). Cells were then serum-starved and placed 
in Boyden chambers to perform the chemo-
invasion assay according to the manufacturer’s 
instructions. After challenging the cells with 
EGF or fetal calf serum, cell migration was 
quantified. As seen in Fig 5b, although EGF 
induced detectable cell migration, the effect of 
serum, possibly due to the number of growth 
factors present, was more prominent. Silencing 
of Tks4 in HeLa cells resulted in a remarkable 
inhibition of cell migration in both EGF- and 
serum-treated cells. To confirm that the 
inhibitory effect of Tks4 was specifically due 
to Tks4 silencing rather then to stress 
responses or other off-target effects Tks4 
siRNA expressing cells were transfected with a 
Tks4 ‘rescue’ expression plasmid mutated 
within the siRNA-targeted sequence (Fig. 5a). 
Expression of the mutant Tks4 cDNA restored 
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the ability of EGF or serum to induce cell 
migration (Fig. 5b).   
 
DISCUSSION 
     In this paper we report a novel role for Tks4 
in the EGF signaling pathway. In our previous 
work we showed that Tks4 was instrumental 
for lamellipodium and membrane ruffle 
formation upon EGF stimulation as well as 
efficient cellular attachment and spreading of 
HeLa cells. In addition, we have demonstrated 
that Tks4/HOFI could associate with cortactin, 
an important protein implicated in cell 
migration (19). Here we completed our 
investigation and established that Tks4 protein 
forms a complex with the EGF receptor and 
becomes tyrosine phosphorylated upon EGF 
stimulation. Tks4 does not contain any typical 
phosphotyrosine binding domain (e.g. SH2 or 
PTB domains) and EGF receptor does not 
possess also any typical proline-rich sequences 
suitable for interaction with any of the SH3 
domains of Tks4 (http://www.uniprot. 
org/uniprot/P00533), therefore it is highly 
likely that the interaction between the two 
proteins is indirect. Furthermore, when we 
used EGFR purified from A431 cells for an in 
vitro kinase assay, as described previously 
(31), we could not detect EGFR-dependent 
tyrosine phosphorylation of Tks4 and also 
could not observe any direct interaction 
between EGFR and Tks4 (data not shown). On 
the other hand, upon EGF treatment of COS7 
cells inducible interaction between Src tyrosine 
kinase and Tks4 was seen. Since the 
interaction of Src kinase with the EGF receptor 
has been well established (20), we propose that 
Src serves as an adaptor molecule which 
bridges between the EGFR and Tks4. This 
model is further supported by our several 
experiments in which the crucial role of Src 
kinase in the tyrosine phosphorylation of Tks4 
upon EGF treatment was underlined: a, the 
specific Src kinase inhibitor PP1 prevented 
Tks4 phosphorylation; b, the triple 
phosphorylation mutant of Tks4, based on the 
phosphorylation sites of Src on Tks4 (12), was 
not capable of tyrosine phosphorylation in 
response to EGF; c, finally, expression of 
either ∆SH2 Src or ∆SH3 Src inhibited the 
association of Tks4 with EGFR . These results 
collectively demonstrate that Tks4 is 
implicated in the EGF signaling pathway by 
forming a complex with the EGFR. The 
interaction of the receptor and the scaffold 
protein is not direct; Src tyrosine kinase may 
serve as a bridging adaptor. In addition, upon 
EGF treatment Src kinase can phosphorylate 
Tks4 on three tyrosine residues; the importance 
of this phosphorylation is not yet clear.  
     Protein-lipid interaction is a well-
underlined mechanism by which eukaryotic 
cells regulate membrane recruitment and 
activation of proteins (26). The family of Tks 
proteins possesses a Phox homology (PX) 
domain which can bind specific membrane 
lipids and is implicated in the appropriate 
cellular localization of Tks4 and Tks5 (7-9,12). 
The PX domain of both Tks4 and Tks5 shows 
a very similar binding affinity, the preferred 
lipids are the lipid products of the PI 3-kinase 
(12). Here we show that the PX domain is 
instrumental for Tks4 to participate properly in 
the EGF signaling pathway. Point mutations 
were introduced into the PX domain of Tks4 
changing the conserved arginines 71 and 94 to 
leucines, as described earlier for other PX 
domains (21-23). Intriguingly, this mutant was 
not able to be phosphorylated on tyrosine 
residues upon EGF treatment. Moreover, when 
cells were pretreated with the specific inhibitor 
of PI 3-kinase, LY294002, EGF-dependent 
tyrosine phosphorylation of Tks4 was also 
markedly inhibited. When subcellular 
localization of endogenous Tks4 was 
monitored by confocal microscopy in EGF 
treated cell, a significant portion of Tks4 was 
seen to be translocated from the cytoplasm to 
the plasma membrane. This effect was 
prevented by addition of PI 3-kinase inhibitor 
LY294002. Based on our findings the 
following model could be proposed: in 
quiescent cells Tks4 is predominantly localized 
in the cytoplasm. EGF stimulation through 
EGFR activates Src tyrosine kinase (20) which 
recruits Tks4 to the plasma membrane and 
phosphorylates it on three tyrosine residues. 
Interestingly, for proper membrane localization 
Tks4 requires its PX domain which can bind to 
the lipid products of PI 3-kinase (Fig 6). It is 
not unique that a regulatory protein requires 
two independent sites for membrane 
translocation. For example, the guanine 
nucleotide exchange factor Sos is recruited to 
the membrane through interactions with the 
SH3 domains of adaptor protein Grb2, while 
its PH domain binds certain phospholipids, 
such as lipid products of PI 3-kinase or 
phosphatidic acid (32,33).  
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      Our data show that Tks4 is involved in the 
regulation of cell migration. Silencing of Tks4 
in HeLa cells resulted in a remarkable 
inhibition of cell migration in both EGF- and 
serum-treated cells. This finding is in 
agreement with the previously suggested role 
of Tks4 in the remodeling of actin 
cytoskeleton, such as cell spreading (19). 
However, currently it is not clear how 
membrane-bound and tyrosine phosphorylated 
Tks4 regulates actin polymerization leading to 
membrane ruffle formation or cell migration. 
One possible downstream candidate is 
cortactin which interacts with Tks4 via its SH3 
domain (19). Cortactin is a well established 
activator of Arp2/3 complex which is the key 
regulator of the branch-chained actin 
polymerization (29,34,35). Interestingly, in 
addition to Tks4 and Tks5 scaffold proteins, 
cortactin is also implicated in the regulation of 
podosome formation (36).  Therefore it is 
likely that cortactin recruited to the membrane 
via Tks4 may contribute either to the formation 
of branched-chain actin polymerization or to 
the development of podosomes. However, 
further experiments will be required to clarify 
how Tks proteins, in concert with cortactin, 
regulate the actin cytoskeleton.  
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FIGURE LEGENDS 
 
Figure 1. Tks4 is tyrosine phosphorylated and associated with the EGF receptor upon EGF treatment 
of cells. (a) Serum-starved A431 cells were stimulated with EGF (50 ng/ml) for 10 min, and then 
endogenous Tks4 was immunoprecipitated (IP) with a polyclonal anti-Tks4 antibody.  After SDS-
PAGE and transfer to nitrocellulose, samples were analysed by anti-phosphotyrosine, anti-EGFR, and 
anti-Tks4 antibodies. (b) Wild type, V5 epitope-tagged Tks4 was transiently expressed in COS7 cells 
and then serum-starved cells were stimulated with EGF or left untreated. Cell lysates were 
immunoprecipitated with anti-V5 antibody and the immunoprecipitates were immunoblotted with anti-
phosphotyrosine, anti-EGFR, and anti-V5 antibodies. These results are representative of three 
experiments.  
 
Figure 2. Src tyrosine kinase interacts with and phosphorylates Tks4 in response to EGF stimulation. 
(a) COS7 cells were transiently transfected with V5-Tks4 construct and after overnight serum-
starvation cells were stimulated with EGF or left untreated. Prior to stimulation the cells were treated 
with the Src kinase inhibitor PP1. Tks4 was immunoprecipitated with anti-V5 antibody and subjected 
to anti-phosphotyrosine and anti-V5 immunoblots. (b) COS7 cells were transiently transfected with 
wild type V5-Tks4 or triple phosphorylation mutant (3xF) V5- Tks4Y25,373,508F constructs. Lysates of 
serum-starved cells were then subjected to immunoprecipitation with anti-V5 antibody. Bound 
proteins were separated by SDS-PAGE, transferred to nitrocellulose, and probed with anti-
phosphotyrosine and anti-V5 antibodies. Results of densitometry of the corresponding bands are also 
indicated. (c)  COS7 cells were transiently transfected with V5-Tks4. Serum-starved cells were treated 
with EGF and Tks4 was immunoprecipitated with anti-V5 antibody. Immunoprecipitates were then 
immunoblotted with anti-Src and V5 antibodies. Immunoblot of lysates used in this experiment shows 
expression levels of Src (bottom panel). These results are typical of at least three experiments. (d) 
Wild type Src, Src mutants lacking either the SH2 (∆SH2 Src) or the SH3 (∆SH3 Src) domains were 
co-expressed with V5-Tks4 in COS7 cells. Serum-starved cells were challenged with EGF for 10 min 
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or left untreated. Tks4 was then immunoprecipitated from cell lysates and immunoprecipitates were 
analyzed by anti-EGFR, anti-V5, and anti-Src antibodies. 
 
Figure 3. EGF induces PI 3-kinase-dependent plasma membrane translocation of Tks4. (a) COS7 
cells were transiently transfected with V5-Tks4 and after serum-starvation cells were stimulated with 
EGF or left untreated. Prior to stimulation the cells were treated with the PI 3-kinase inhibitor 
LY294002. Tks4 proteins were immunoprecipitated with anti-V5 antibody and subjected to anti-
phosphotyrosine and anti-V5 immunoblots. (b) COS7 cells were transiently transfected with wild type 
V5-Tks4 and V5-Tks4R71,94L constructs and challenged with EGF. Cell lysates were then subjected to 
immunoprecipitation with anti-V5 antibody. Bound proteins were separated by SDS-PAGE, 
transferred to nitrocellulose, and probed with anti-phosphotyrosine and anti-V5 antibodies. Results of 
densitometry of the corresponding bands are also indicated. (c) Serum-starved COS7 cells were 
stimulated with EGF (B) or left untreated (A). Prior to stimulation with EGF, cells were treated with 
the PI 3-kinase inhibitor LY294002 (C). Cells were then fixed and processed for immunofluorescence. 
Endogenous expression and subcellular localization of Tks4 were detected using a Tks4-specific 
polyclonal antibody. Arrows indicate Tks4 present at the plasma membrane. The scale bar represents 
20 µm. (d) The percentage of cells with Tks4-immunreactivity in membrane ruffles under serum-
starved condition or after EGF or EGF+LY294002 treatments was quantified by an observer who was 
blinded to cell treatment status (n = 100 cells for each group per experiment).  
 
Figure 4. Tks4R43W mutant shows aberrant intracellular expression and reduced phosphoinositide 
binding. (a) COS7 cells were transiently transfected with wild type V5-Tks4 or V5-Tks4R43W 
constructs and challenged with EGF. Cell lysates were then subjected to immunoprecipitation with 
anti-V5 antibody. Bound proteins were separated by SDS-PAGE, transferred to nitrocellulose, and 
probed with anti-phosphotyrosine and anti-V5 antibodies. Results of densitometry of the 
corresponding bands are also indicated. (b) The lipid-binding ability of GST-PX (left panel) and GST-
PX carrying a mutation (R43W, right panel) of Tks4 was tested in protein-lipid overlay assay. Layout 
of the PIP strip was the following: 1. Lysophosphatidic acid 2. Lysophosphatidylcholine 3. 
Phosphatidylinositol (PtdIns) 4. PtdIns(3)P 5. PtdIns(4)P 6. PtdIns(5)P 7. Phosphatidylethanolamine 8. 
Phosphatidylcholine 9. Sphingosine 1-phosphate 10. PtdIns(3,4)P2 11. PtdIns(3,5)P2 12. PtdIns(4,5)P2 
13. PtdIns(3,4,5)P3 14. Phosphatidic acid 15. Phosphatidylserine 16. Blank. (c) COS7 cells were 
transiently transfected with V5-Tks4, V5-Tks4R43Q or V5-Tks4R43W. After 48 h, cells were fixed and 
stained for Tks4 with anti-V5 antibody. Cell nuclei were visualized by DAPI staining. Arrows indicate 
Tks4 aggregates close to the nucleus. The scale bar represents 20 µm. (d) The percentage of cells with 
Tks4-immunreactivity in membrane ruffles under serum-starved condition or after EGF treatment was 
quantified by an observer who was blinded to cell treatment status (n = 100 cells for each group per 
experiment). Asterisk indicates P < 0.005. 
 
Figure 5. Tks4 silencing inhibits EGF- and serum-dependent cell migration. (a) HeLa cells were 
transfected with control and Tks4-specific stealth siRNA duplexes as well as with siRNA-resistant 
V5-Tks4 (Tks4 rescue) constructs. 48 h later cells were harvested and lysates were immunoblotted 
with anti-Tks4 antibody. Actin was used as a loading control for cell lysates. Results of densitometry 
of the corresponding bands are also indicated. (b) HeLa cells were transfected with control, Tks4-
specific stealth siRNA duplexes, and Tks4-specific siRNA duplexes together with a siRNA-resistant 
Tks4 construct (Tks4 rescue). Cells were then harvested and tested using a modified Boyden chamber 
assay as described in “Methods”. After 24 h, migrated cells were quantified according to the 
manufacturer’s protocol. Error bars represent the standard error of the mean, SEM, of three 
independent experiments. Asterisk indicates P < 0.005. 
 
 
Figure 6. Proposed model of Tks4 activation upon EGF stimulation. In quiescent cells, Tks4 is 
basically present in the cytoplasm. In response to growth factor treatment, Tks4 is translocated to the 
plasma membrane through at least two independent sites: an Src-binding site and its lipid binding PX 
domain. The Tks4 PX domain may recognize lipid products of PI 3-kinase in the membrane. At the 
plasma membrane, Tks4 is tyrosine phosphorylated by Src kinase. The role of Tks4 tyrosine 
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phosphorylation is currently not known. Finally, Tks4 may signal toward podosome formation or the 
actin cytoskeleton. One of the known binding partners of Tks4 is cortactin, an important activator of 
the Arp2/3 complex.  
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